Sign Up for Email Alerts
Kineta Inc.
Kineta Inc.
Kineta Inc.
Close
  • About Us
    • company
    • team
    • board
    • SAB
  • pipeline
    • overview
    • KVA12123 (VISTA)
    • CD27
  • partnerships
  • investors
    • overview
    • press releases
    • events & presentations
    • stock information
    • analyst coverage
    • SEC filings
    • corporate governance
    • IRS Form 8937
  • careers
  • contact
  • en_USEnglish
    • ko_KRKorean
  • About Us
    • company
    • team
    • board
    • SAB
  • pipeline
    • overview
    • KVA12123 (VISTA)
    • CD27
  • partnerships
  • investors
    • overview
    • press releases
    • events & presentations
    • stock information
    • analyst coverage
    • SEC filings
    • corporate governance
    • IRS Form 8937
  • careers
  • contact
  • en_USEnglish
    • ko_KRKorean

[be_recent_posts_author_no_link title=”Latest News from Kineta” category_id=”4,3″ num_posts=”6″ post_offset=”0″ num_words_limit=”0″ show_date_author=”1″ show_more_link=”0″ more_link_text=”Read more” show_thumbs=”0″ remove_thumb_frame=”0″ thumb_frame_shadow=”0″ default_thumb=”0″ post_thumb_width=”100″ post_thumb_height=”80″]

Recent Kineta News

  • TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.
  • Kineta Updates KVA12123 Clinical Results from Ongoing Phase 1/2 VISTA101 Study at Society for Immunotherapy of Cancer (2024)
  • Kineta Announces Completion of Enrollment in the Monotherapy Arm of the VISTA-101 Phase 1 Clinical Study in Advanced Solid Tumors
  • Kineta Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024
  • Kineta Announces the Extension of the TuHURA Biosciences Exclusivity and Right of First Offer Agreement for KVA12123, Kineta’s VISTA blocking antibody Currently in Phase 1
Post placeholder image
August 9, 2017 in Biotech Industry News

Prospects Identified for Iimmunotherapy Treatments

Kineta Inc 0 Like Post Comments Off on Prospects Identified for Iimmunotherapy Treatments
Read More
Post placeholder image
June 20, 2017 in Biotech Industry News

VIDEO: Non-addictive painkiller, KIRO 7

Kineta Inc 0 Like Post Comments Off on VIDEO: Non-addictive painkiller, KIRO 7
Read More
Post placeholder image
June 20, 2017 in Biotech Industry News

Seattle drug company working on non-addictive, non-opioid painkiller, MyNorthwest

Kineta Inc 0 Like Post Comments Off on Seattle drug company working on non-addictive, non-opioid painkiller, MyNorthwest
Read More
Post placeholder image
June 19, 2017 in Biotech Industry News

Inside Perspectives: Will Immunotherapy Knock Out Cancer?, WuXi AppTec

Kineta Inc 0 Like Post Comments Off on Inside Perspectives: Will Immunotherapy Knock Out Cancer?, WuXi AppTec
Read More
Post placeholder image
May 15, 2017 in Biotech Industry News

Inside Perspectives on Cancer Immunotherapy: An Interview with Kineta’s Shawn Iadonato, WuXi AppTec

Kineta Inc 1 Like Post Comments Off on Inside Perspectives on Cancer Immunotherapy: An Interview with Kineta’s Shawn Iadonato, WuXi AppTec
Read More
Post placeholder image
May 15, 2017 in Biotech Industry News

The Hunt For Non-Opioid, Non-Addictive Painkillers, American Council on Science and Health

Kineta Inc 1 Like Post Comments Off on The Hunt For Non-Opioid, Non-Addictive Painkillers, American Council on Science and Health
Read More
Post placeholder image
May 4, 2017 in Biotech Industry News

RLR Agonists Seen to Promote Immune Response Against Colon Cancer Cells in Early Study, Colon Cancer News Today

Kineta Inc 1 Like Post Comments Off on RLR Agonists Seen to Promote Immune Response Against Colon Cancer Cells in Early Study, Colon Cancer News Today
Read More
Post placeholder image
March 4, 2017 in Biotech Industry News

A little mollusk may lead to a big discovery in helping solve the U.S. opioid epidemic

Kineta Inc 1 Like Post Comments Off on A little mollusk may lead to a big discovery in helping solve the U.S. opioid epidemic
Read More
Post placeholder image
February 22, 2017 in Biotech Industry News

Biotech startup tries unique weapon in fight against chronic pain and opioid addiction: snail venom

Kineta Inc 1 Like Post Comments Off on Biotech startup tries unique weapon in fight against chronic pain and opioid addiction: snail venom
Read More
Post placeholder image
February 22, 2017 in Biotech Industry News

Biggest Northwest angel group Keiretsu details its top Seattle-area investments

Kineta Inc 1 Like Post Comments Off on Biggest Northwest angel group Keiretsu details its top Seattle-area investments
Read More
Prev1…3456Next

219 Terry Ave. N. Suite 300. Seattle, WA 98109

Sign Up for Email Alerts

219 Terry Ave. N. Suite 300. Seattle, WA 98109

  • About Us
  • pipeline
  • partnerships
  • investors
  • contact
Sign Up for Email Alerts

© 2025 Kineta Inc.        Privacy Policy       Terms of Use

English
English
Korean